Skip to main content
. 2016 Jun 28;24(10):1734–1744. doi: 10.1038/mt.2016.109

Figure 5.

Figure 5

Discoidin domain receptor 2 (DDR2) -targeting strategies have therapeutic efficacy against lung fibrosis. (a,b) The expression and activation pattern of DDR2 during bleomycin-induced lung fibrosis. Lung tissues from bleomycin-treated C57BL/6 mice were collected at various time points for analysis of the mRNA (a) and protein (b) expression of the indicated genes. The histograms in b depict results quantified using densitometry scanning. (c,d) Late treatment with DDR2 small interfering RNA (siRNA) still potently inhibits the development of lung fibrosis. 1 day after bleomycin instillation, C57BL/6 mice were treated with siRNA immediately or from 14 days later. At day 28, the mouse lungs were subjected to Hematoxylin and Eosin (H&E) staining c and immunoblot analysis d. (e,f) DDR2 kinase inhibitor dasatinib attenuates pulmonary fibrosis. Fourteen days after bleomycin treatment, the C57BL/6 mice received daily oral gavage of dasatinib. Two weeks later, the mouse lung tissues were collected for analysis of the lung structure e and vascular density f. The histogram in f represents the percentage of CD31 staining. **P < 0.001.